[1]
|
Uddin, A. and Chakraborty, S. (2018) Role of miRNAs in Lung Cancer. Journal of Cellular Physiology. (Preprint)
https://doi.org/10.1002/jcp.26607
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. https://doi.org/10.3322/caac.21387
|
[3]
|
Wu, Y.B., Xu, L.L., Wang, X.J., Wang, Z., Zhang, J., Tong, Z.H., et al. (2017) Diagnostic Value of Medical Thoracoscopy in Malignant Pleural Ef-fusion. BMC Pulmonary Medicine, 17, Article No. 109.
https://doi.org/10.1186/s12890-017-0451-1
|
[4]
|
Ryu, J.S., Ryu, H.J., Lee, S.N., Memon, A., Lee, S.K., Nam, H.S., et al. (2014) Prognostic Impact of Minimal Pleural Effusion in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 32, 960-967.
https://doi.org/10.1200/JCO.2013.50.5453
|
[5]
|
Keeratichananont, W., Limthon, T. and Keeratichananont, S. (2015) Efficacy and Safety Profile of Autologous Blood versus Tetracycline Pleurodesis for Malignant Pleural Effusion. Thera-peutic Advances in Respiratory Disease, 9, 42-48.
https://doi.org/10.1177/1753465815570307
|
[6]
|
Usui, K., Sugawara, S., Nishitsuji, M., Fujita, Y., Inoue, A., Mouri, A., et al. (2016) A Phase II Study of Bevacizumab with Carboplatin-Pemetrexed in Non-Squamous Non-Small Cell Lung Carcinoma Patients with Malignant Pleural Effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer, 99, 131-136.
https://doi.org/10.1016/j.lungcan.2016.07.003
|
[7]
|
Koegelenberg, C.F.N., Shaw, J.A., Irusen, E.M. and Lee, Y.C.G. (2018) Contemporary Best Practice in the Management of Malignant Pleural Effusion. Therapeutic Advances in Respiratory Disease, 12.
https://doi.org/10.1177/1753466618785098
|
[8]
|
中国恶性胸腔积液诊断与治疗专家共识组. 恶性胸腔积液诊断与治疗专家共识[J]. 中华内科杂志, 2014, 53(3): 252-256.
|
[9]
|
American Thoracic Society (2000) Management of Malignant Pleural Effusions. American Journal of Respiratory and Critical Care Medicine, 162, 1987-2001. https://doi.org/10.1164/ajrccm.162.5.ats8-00
|
[10]
|
Shaw, P. and Agarwal, R. (2004) Pleurodesis for Malignant Pleural Effusions. Cochrane Database of Systematic Reviews, No. 1, Article ID: CD002916. https://doi.org/10.1002/14651858.CD002916.pub2
|
[11]
|
Dresler, C.M., Olak, J., Herndon II, J.E., Richards, W.G., Scalzetti, E., Fleishman, S.B., et al. (2005) Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Ma-lignant Pleural Effusion. Chest, 127, 909-915.
https://doi.org/10.1378/chest.127.3.909
|
[12]
|
Olivares-Torres, C.A., Laniado-Laborín, R., Chávez-García, C., Le-ón-Gastelum, C., Reyes-Escamilla, A. and Light, R.W. (2002) Iodopovidone Pleurodesis for Recurrent Pleural Effusions. Chest, 122, 581-583.
https://doi.org/10.1378/chest.122.2.581
|
[13]
|
Ibrahim, I.M., Dokhan, A.L., El-Sessy, A.A. and Eltaweel, M.F. (2015) Povidone-Iodine Pleurodesis versus Talc Pleurodesis in Preventing Recurrence of Malignant Pleural Effusion. Journal of Cardiothoracic Surgery, 10, Article No. 64. https://doi.org/10.1186/s13019-015-0270-5
|
[14]
|
Ide, A.G., Baker, N.H. and Warren, S.L. (1939) Vascularization of the Brown Pearce Rabbit Epithelioma Transplant as Seen in the Transparent Ear Chamber. The American Journal of Roentgenology, 42, 891-899.
|
[15]
|
Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S. and Dvorak, H.F. (1983) Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid. Science, 219, 983-985.
https://doi.org/10.1126/science.6823562
|
[16]
|
Ferrara, N. and Henzel, W.J. (1989) Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells. Biochemical and Biophysical Research Communications, 161, 851-858.
https://doi.org/10.1016/0006-291X(89)92678-8
|
[17]
|
Bates, D.O. (2010) Vascular Endothelial Growth Factors and Vascular Permeability. Cardiovascular Research, 87, 262-271. https://doi.org/10.1093/cvr/cvq105
|
[18]
|
刘玉杰, 田攀文. 贝伐珠单抗治疗非小细胞肺癌所致恶性胸腔积液的研究进展[J]. 中国肺癌杂志, 2019, 22(2): 118-124.
|
[19]
|
Popper, H.H. (2016) Progression and Metastasis of Lung Cancer. Cancer and Metastasis Reviews, 35, 75-91.
https://doi.org/10.1007/s10555-016-9618-0
|
[20]
|
白春学, 陈良安, 胡成平, 李为民, 周建英, 白冲, 宋勇. 晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识(2016年版) [J]. 中华结核和呼吸杂志, 2016, 39(11): 839-849.
|
[21]
|
Di, W., Yue, C., Ziran, Z., Jie, Z., Jun, N., Ling, D., et al. (2022) A Phase II Study of Bevacizumab in Non-Squamous, Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusion. Future Oncology, 18, 669-677.
https://doi.org/10.2217/fon-2021-1035
|
[22]
|
Chen, D., Song, X., Shi, F., Zhu, H., Wang, H., Zhang, N., et al. (2017) Greater Efficacy of Intracavitary Infusion of Bevacizumab Compared to Traditional Local Treatments for Patients with Malignant Cavity Serous Effusion. Oncotarget, 8, 35262-35271. https://doi.org/10.18632/oncotarget.13064
|
[23]
|
Xu, X., Mao, W., Chen, Q., Zhuang, Q., Wang, L., Dai, J., et al. (2014) Endostar, a Modified Recombinant Human Endostatin, Suppresses Angiogenesis through Inhibition of Wnt/β-Catenin Signaling Pathway. PLOS ONE, 9, e107463.
https://doi.org/10.1371/journal.pone.0107463
|
[24]
|
Fukumoto, S., Morifuji, M., Katakura, Y., Ohishi, M. and Nakamura, S. (2005) Endostatin Inhibits Lymph Node Metastasis by a Down-Regulation of the Vascular Endothelial Growth Factor C Expression in Tumor Cells. Clinical & Experimental Metastasis, 22, 31-38. https://doi.org/10.1007/s10585-005-3973-5
|
[25]
|
Li, K., Shi, M. and Qin, S. (2018) Current Status and Study Pro-gress of Recombinant Human Endostatin in Cancer Treatment. Oncology and Therapy, 6, 21-43. https://doi.org/10.1007/s40487-017-0055-1
|
[26]
|
Qin, S., Yang, L., Liang, J., Cheng, Y., Tan, Q., Bi, J., Wang, L., Hu, B., Shi, J., Sun, G., et al. (2017) Prospective, Randomized, Multicenter Clinical Study of Endometrial and Cisplatin in the Treatment of Malignant Pleural Effusion. Chinese Journal of Clinical Oncology, 22, 193-202.
|
[27]
|
Rong, B., Cai, X., Liu, H., Gao, W. and Yang, S. (2016) Thoracic Perfusion of Recombinant Human Endostatin (Endostar) Combined with Chemotherapeutic Agents versus Chemotherapeutic Agents alone for Treating Malignant Pleural Effusions: A Sys-tematic Evaluation and Meta-Analysis. BMC Cancer, 16, Article No. 888.
https://doi.org/10.1186/s12885-016-2935-4
|
[28]
|
李业锦. 不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床分析[J]. 吉林医学, 2019, 40(5): 928-929.
|
[29]
|
刘自力, 黄礼年, 王斌, 刘继柱, 刘伟伟. 恩度联合顺铂治疗非小细胞肺癌合并恶性胸腔积液的Meta分析[J]. 中国循证医学杂志, 2016(5): 557-563.
|
[30]
|
张树林, 闫其涛. 观察不同剂量顺铂胸腔内注射疗法在肺癌恶性胸腔积液患者中的应用效果[J]. 中国现代药物应用, 2018, 12(23): 68-70.
|
[31]
|
徐世新, 姚舒, 陆淑凤. 重组白介素2联合卡铂胸腔内灌注治疗恶性胸腔积液临床观察[J]. 中国当代医药, 2010, 17(34): 61+69.
|
[32]
|
陈婧, 李冬雷, 张旭宇, 高玉华, 王艳丽. 贝伐单抗与卡铂结合治疗非小细胞肺癌恶性胸腔积液的疗效[J]. 实用癌症杂志, 2020, 35(2): 208-211.
|
[33]
|
朱姝, 刘淮东, 杨秋云, 李娟, 王惠. 奈达铂及顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床疗效及预后对比[J]. 湖南师范大学学报(医学版), 2022, 19(1): 163-166.
|
[34]
|
闵诗惠, 郑强强, 张白露, 严丹丽, 王汝兰, 瞿子涵, 等. 洛铂与顺铂胸腔灌注化疗治疗恶性胸腔积液的疗效及不良反应的Meta分析[J]. 中国肺癌杂志, 2019, 22(2): 90-98. https://doi.org/10.3779/j.issn.1009-3419.2019.02.03
|
[35]
|
戴莉莉. 恶性胸腔积液的生物免疫治疗进展[J]. 上海医药, 2011, 32(2): 80-82.
|
[36]
|
刘占伟, 卞丹阳, 申国宏, 石磊. 白细胞介素-2联合顺铂治疗肺癌所致恶性胸腔积液[J]. 武警医学院学报, 2007, 16(4): 437-438.
|
[37]
|
孙永苹, 汪成琼, 陈玲, 李娜娜, 姚新生, 肖政. 白细胞介素2联合顺铂治疗恶性胸腔积液有效性及安全性的Meta分析[J]. 重庆医学, 2017, 46(1): 84-89+93.
|
[38]
|
沈红梅, 黄杰, 段林灿, 王轶珊. 中药制剂胸腔内灌注治疗恶性胸腔积液现状[J]. 山东医药, 2011, 51(32): 110-111.
|
[39]
|
Lin, Z., Jiang, M., Gao, L. and Zhang, H. (2020) The Clinical Efficacy of Traditional Chinese Medicine in the Treatment of Malignant Pleural Effusion: A Protocol of Systematic Review and Meta-Analysis. Medicine, 99, e22403.
https://doi.org/10.1097/MD.0000000000022403
|